Tilmann Burckstummer, PhD profile page

Tilmann has been a CRISPR enthusiast since the early days of CRISPR. Originally trained as a biochemist, he joined Haplogen as principal scientist and later became their CSO. Following the acquisition by Horizon Discovery, Tilmann served as Director R&D and, later, Head of Innovation, where he oversaw Horizon’s technology platform and innovation agenda. In 2018, he co-founded Myllia Biotechnology, which focuses on single-cell CRISPR screens. He is also the CEO of bit.bio discovery, a joint venture between Vienna-based Myllia Biotechnology and Cambridge-based bit.bio. Tilmann is passionate about science and enjoys working with multi-disciplinary and multi-national teams.